COVAXIN: India’s first COVID-19 Vaccine trials
Published: July 1, 2020
The Central Drugs and Standard Control Organization has granted its approval to conduct human trials of COVAXIN vaccine. The vaccine was developed by Bharat Biotech India.
The trials are to begin in July 2020.
The trials of the vaccine are scheduled to begin by July, 2020. The vaccine was developed in collaboration with Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV)
About the Trials
The clinical trials of COVAXIN are to be conducted in two phases. The trials are to test for safety rather than efficacy.
COVAXIN is an indigenously developed vaccine. It is an inactivated vaccine. An inactivated vaccine is developed by culturing (growing) virus on a large scale. The inactive form of the virus is then injected into human body. This will force the immune system of the human body to develop antibodies against the virus. However, no harm is induced as the virus will stay in their inactive state.
It is a Hyderabad based biotechnology company. It is known for its first indigenously developed cell culture H1N1 Swine Flu Vaccine.
The company developed the vaccine in its Bio Safety Level 3 laboratory.
Month: Current Affairs - July, 2020